Shares of Pharvaris N.V. (PHVS) surged 5.94% on Friday, marking a strong finish to the trading week for the biopharmaceutical company. The stock's intraday surge came amid bullish analyst sentiment.
Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris and set a price target of $34.00, reflecting a significant upside potential from current levels. The analyst's positive outlook appears to be fueling investor optimism and driving the stock higher.
Pharvaris is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare diseases. The company's promising pipeline and growth prospects have caught the attention of Wall Street analysts, contributing to the stock's recent momentum.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。